Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triheptanoin for Long-chain Fatty Acid Beta-oxidation Defects
NCT02201368Phase 3Withdrawn
- Start
- Nov 2009
- Primary completion
- Mar 2010
- Modality
- SLNs, Nanostructured Lipid Carriers, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of triheptanoin in Long Chain Fatty Acid Oxidation Disorders (LC-FAOD). Planned start Nov 2009; status: withdrawn.
02
Drugs
triheptanoin
03
Conditions
Long Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Beyond the preview
Go deeper on NCT02201368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02201368.